Presentation is loading. Please wait.

Presentation is loading. Please wait.

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,

Published byNoel Walker Modified over 9 years ago

Similar presentations

Presentation on theme: "CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,"— Presentation transcript:

1 CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner, Giuseppe Basso, Giuseppe Gaipa, Michael N. Dworzak, Renate Kirschner-Schwabe, Christian Hagemeier, Martin Stanulla, Martin Schrappe, Wolf-Dieter Ludwig, Leonid Karawajew, and Richard Ratei Blood Volume 115(18):3763-3771 May 6, 2010 ©2010 by American Society of Hematology

2 Correlation of CD11b mRNA at diagnosis with percentage of blasts at day 8. Peter Rhein et al. Blood 2010;115:3763-3771 ©2010 by American Society of Hematology

3 ROC curve analysis of discrimination of FCM-MRD remission status (FCM positive vs negative) and BFM risk stratification (high vs standard) according to CD11b expression levels at diagnosis. Peter Rhein et al. Blood 2010;115:3763-3771 ©2010 by American Society of Hematology

4 CD11b protein expression is consistently increased in MRD cells. Peter Rhein et al. Blood 2010;115:3763-3771 ©2010 by American Society of Hematology

5 CD11b expression in ALL blasts under therapy: modulation vs selection. Peter Rhein et al. Blood 2010;115:3763-3771 ©2010 by American Society of Hematology

6 CD11b positivity improves discrimination between ALL and normal mature and precursor B cells. Peter Rhein et al. Blood 2010;115:3763-3771 ©2010 by American Society of Hematology

Download ppt "CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,"

Similar presentations

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk.

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk.
Identification and functional characterisation of molecular risk factors in acute leukemias Renate Kirschner 1, Michaela Heide 1, Peter Rhein 1, Leonid.

Identification and functional characterisation of molecular risk factors in acute leukemias Renate Kirschner 1, Michaela Heide 1, Peter Rhein 1, Leonid.
Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor.

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor.
MicroRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia by Daniela Asslaber, Josefina.

MicroRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia by Daniela Asslaber, Josefina.
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms by Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser,

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms by Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser,
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,
Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
MiRNA-130a regulates C/EBP-ε expression during granulopoiesis by Maria T. Larsen, Mattias Häger, Andreas Glenthøj, Fazila Asmar, Stine N. Clemmensen, Helena.

MiRNA-130a regulates C/EBP-ε expression during granulopoiesis by Maria T. Larsen, Mattias Häger, Andreas Glenthøj, Fazila Asmar, Stine N. Clemmensen, Helena.
Figure 2 Percentage of CD19+/CD34+ cells with decreased CD81 median fluorescence intensity (MFI;

Figure 2 Percentage of CD19+/CD34+ cells with decreased CD81 median fluorescence intensity (MFI;
Early T-Cell Precursor ALL in 5 Year Old Female

Early T-Cell Precursor ALL in 5 Year Old Female
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study by Martin Schrappe, Maria.

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study by Martin Schrappe, Maria.
Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification by Estella.

Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification by Estella.
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.
Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology.

Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology.
Next-generation leukemia immunotherapy

Next-generation leukemia immunotherapy
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

Similar presentations

Ads by Google